Halozyme Therapeutics Inc. has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated, through which Vertex has licensed Halozyme’s Hypercon technology for use in up to three drug targets. Hypercon is a microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration.

“This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable small volume, patient-delivered next‑generation biologics,” said Helen Torley, President and CEO of Halozyme. “Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases.”

“We are pleased to add Halozyme’s Hypercon drug delivery technology to our toolbox as we pursue transformative therapies for patients with serious diseases,” said Mark Bunnage, D.Phil., Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals. “We look forward to exploring the full potential of this technology across our programs of interest.”

Under the terms of the exclusive agreement, Vertex will make a $15 million upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products developed using the Hypercon technology.

More Halozyme News

Earlier this year, Halozyme Therapeutics entered into a global collaboration and exclusive license agreement with Takeda, which provides Takeda with access to Halozyme’s ENHANZE drug delivery technology.